Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1504 participants.
Also called NCT01674647
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose prevention
- Phase
- Phase 3
- Enrolled
- 1,504 participants
- Registry
-
NCT01674647 -
2011-002234-39
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- United States, Belgium, Brazil, Canada, China, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Portugal, Singapore, South Africa, Spain, United Kingdom
- Registry status
- Completed
Technical summary
Registry record NCT01674647. Randomized; no masking; primary purpose prevention. Start 2012-10 (registry gives no type); primary completion 2014-01 (actual). Results posted on 2015-02-03.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Explore the Efficacy and Safety of Once-daily Oral Rivaroxaban for the Prevention of Cardiovascular Events in Subjects With Nonvalvular Atrial Fibrillation Scheduled for Cardioversion
- Acronym
- X-VERT
- Condition
- Atrial Fibrillation
- Intervention (Drug)
- Rivaroxaban (Xarelto, BAY59-7939)
- Intervention (Drug)
- Vitamin K antagonist (VKA)
- Lead sponsor
- Bayer
- Collaborator
- Janssen Research & Development, LLC
Record details
- Record id
cardio:ct-nct01674647- Content hash
8b2c7d8637e75c2dcf45d6c18a5ff40392a646375dc6e657f5da9bc9807473d2